AI Article Synopsis
- Ensifentrine (RPL554) is an inhaled medication that acts as a dual phosphodiesterase 3/4 inhibitor, meaning it helps relax airways and reduce inflammation.
- It is currently being investigated as a treatment option for chronic obstructive pulmonary disease (COPD) and other inflammatory airway conditions.
- The specific role of Ensifentrine in COPD management is still uncertain, as it may serve as either an add-on treatment during acute flare-ups or as a regular maintenance therapy, possibly alongside other medications.
Article Abstract
Ensifentrine (RPL554), an inhaled 'bifunctional' dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities, provides a new option in the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases that are under clinical development. Ensifentrine appears to be initially under development for the treatment of COPD although it is not yet clear whether it should be understood as an add-on therapy in patients for the treatment of acute exacerbations of COPD or for the regular maintenance treatment of patients either alone, or on top of existing drug classes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/ppa-2018-0030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Respir Investig
December 2024
Hamad Medical Corporation, Al Rayyan Road, Doha, 3050, Qatar. Electronic address:
Background: We evaluated the efficacy and safety of Ensifentrine in COPD via a systematic review and meta-analysis of randomized controlled trials (RCTs).
Methods: We performed a detailed literature search on Medline (via PubMed), Scopus, Google Scholar, and Cochrane on the basis of pre-specified eligibility criteria. We used Review Manager to calculate pooled mean differences (MD) and 95% Confidence Interval (CI) using a random effects model.
Phosphodiesterase Inhibition as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease: Where We Have Been and What Lies Ahead.
Chronic Obstr Pulm Dis
December 2024
Harvard Medical School, Boston, Massachusetts, United States.
Chronic obstructive pulmonary disease (COPD) is a highly prevalent inflammatory lung condition characterized by chronic respiratory symptoms and airflow obstruction that often lead to diminished quality of life. Non-pharmacologic management for patients with COPD involves smoking cessation and healthy lifestyle changes. Pharmacologic treatments include inhaled bronchodilators with or without the use of inhaled corticosteroids, which can be administered through inhalation or nebulization.
View Article and Find Full Text PDFThe need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease.
Expert Rev Clin Pharmacol
December 2024
Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Introduction: The therapeutic implications of phosphodiesterase (PDE) inhibitors have attracted interest because PDEs are regarded as an intracellular target to be exploited for therapeutic advancements in the treatment of COPD. At present, the only approved approach for the treatment of COPD with PDE inhibitors is the use of an oral PDE4 inhibitor. However, this treatment is not widely employed, primarily due to the narrow therapeutic index associated with oral PDE4 inhibitors, which significantly limits the tolerable dose.
View Article and Find Full Text PDFGoals of chronic obstructive pulmonary disease management: a focused review for clinicians.
Curr Opin Pulm Med
December 2024
Integrated Hospital-Care Institute, Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Purpose Of Review: The diagnosis of chronic obstructive pulmonary disease (COPD) encompasses heterogeneous pathophysiological mechanisms which can shape an individual patient's experience. This paper reviews available therapeutic options for the clinician intending to individualize care toward patient goals.
Recent Findings: The contemporary targeted interventions for COPD include the novel phosphodiesterase inhibitor ensifentrine, the interleukin-4 receptor (IL4R alpha subunit) antibody dupilumab, augmentation therapy for alpha-1 antitrypsin deficiency.
Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis.
Respir Med
November 2024
Research and Enterprise, University of Cyberjaya, Persiaran Bestari, Cyber 11, 63000, Cyberjaya, Selangor, Malaysia; Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India. Electronic address:
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!